跳转至内容
Merck
CN

1357056

USP

Leflunomide Related Compound B

United States Pharmacopeia (USP) Reference Standard

别名:

2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)crotonamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C12H9F3N2O2
分子量:
270.21
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

leflunomide

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1

InChI

1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-

InChI key

UTNUDOFZCWSZMS-YFHOEESVSA-N

基因信息

human ... DHODH(1723)

正在寻找类似产品? 访问 产品对比指南

一般描述

Leflunomide Related Compound B (2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)crotonamide is a malononitrilamide which is a water soluble metabolite of Leflunomide. It is considered as a noncompetitive inhibitor of dihydro-orotate dehydrogensae. This metabolite has been reported to initially target activated lymphocytes.

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Takeo Sato et al.
Rheumatology (Oxford, England), 48(10), 1265-1268 (2009-08-05)
To elucidate the factors associated with poor prognosis of LEF-induced lung injury in patients with RA. The background and clinical and laboratory features of LEF-induced lung injury were examined and compared between patients who died of and who recovered from
Paola Montagna et al.
Annals of the New York Academy of Sciences, 1193, 30-35 (2010-04-20)
Rheumatoid arthritis (RA) prevalence is greater in females than in males, supporting estrogens as modulators of immune response. Leflunomide (LEF) is employed in the RA treatment. We studied the combinatory effects of LEF active metabolite A77 1726 (LEF-M) and 17beta-estradiol
Yu-cong Yuan et al.
Zhonghua yi xue za zhi, 91(10), 703-706 (2011-05-24)
To explore the therapeutic effects of leflunomide metabolite A771726 on high glucose-induced podocyte injury and understand its mechanism. The conditionally immortal human glomerular podocytes were divided into normal glucose group (NG), high glucose group (HG), mannitol group (MA), high glucose
Li-Xia Xiong et al.
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 25(1), 16-19 (2009-01-08)
To observe the inhibitory effects of tyrosine kinases inhibitor A77 1726 on collagen generation induced by IL-13 in fibroblasts. The inhibition rate of fibroblast proliferation with different concentration of A77 1726 was observed by MTT method. The fibroblasts were divided
Eva Bernhoff et al.
Journal of virology, 84(4), 2150-2156 (2009-12-04)
The immunomodulatory drug leflunomide is frequently used for treating polyomavirus-associated nephropathy, yet its antiviral mechanism is unclear. We characterized the effects of the active leflunomide metabolite A771726 (LEF-A) on the polyomavirus BK (BKV) life cycle in human renal tubular epithelial

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门